Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Executive Summary
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia
You may also be interested in...
Combo Drug Commercial Potential May Be Lowered By D.C. Court Ruling
A Washington, D.C. federal appeals court ruling could have a significant impact on pharmaceutical companies that are eying combination therapies as growth drivers
Pfizer Stops Swinging For The Fences; Combo Products Are Big Opportunity
Pfizer is investing more heavily in low-risk "product enhancements" to help round out its R&D portfolio
Lipitor Scripts Rebounding, Pfizer Says; Cholesterol Category Still Has Life
Pfizer sees signs of a rebound in Lipitor (atorvastatin) prescriptions over the past six weeks, U.S. Pharmaceuticals President Pat Kelly said during Pfizer's June 17 analysts meeting in New York